Table 1.

ATM-relevant trials

DDR targetDrug nameNCT identifierPhaseStudy sizeATM status consideredStudy title (pancreatic cancer eligible trials are in bold)
ATMAZD0156NCT02588105I83NoStudy to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination with Other Anticancer Treatment in Patients with Advanced Cancer (AToM)
AZD1390NCT03423628I132NoA Study to Assess the Safety and Tolerability of AZD1390 Given with Radiation Therapy in Patients with Brain Cancer
ATRM6620 (VX-970)NCT02723864I60NoVeliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination with Cisplatin in People with Refractory Solid Tumors
M6620 (VX-970)NCT02595931I51NoVX-970 and Irinotecan Hydrochloride in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
M6620 (VX-970)NCT03641313II28Exploratory objectiveATR Kinase Inhibitor M6620 and Irinotecan in Treating Patients with Progressive, Metastatic, or Unresectable TP53-Mutant Gastric or Gastroesophageal Junction Cancer
M6620 (VX-970)NCT03517969II130NoATR Kinase Inhibitor VX-970 and Carboplatin with or without Docetaxel in Treating Participants with Metastatic Castration-Resistant Prostate Cancer
M6620 (VX-970)NCT02567409II90NoCisplatin and Gemcitabine Hydrochloride with or without ATR Kinase Inhibitor M6620 in Treating Patients with Metastatic Urothelial Cancer
M6620 (VX-970)NCT02595892II70NoGemcitabine Hydrochloride Alone or with M6620 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M6620 (VX-970)NCT02627443I111NoCarboplatin and Gemcitabine Hydrochloride with or without ATR Kinase Inhibitor VX-970 in Treating Patients with Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M6620 (VX-970)NCT02487095I/II70NoTrial of Topotecan with VX-970, an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
M6620 (VX-970)NCT03641547I65NoM6620 plus Standard Treatment in Oesophageal and Other Cancer (CHARIOT)
M6620 (VX-970)NCT02567422I45NoM6620, Cisplatin, and Radiation Therapy in Treating Patients with Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma
M6620 (VX-970)NCT02589522I46NoVX-970 and Whole Brain Radiation Therapy in Treating Patients with Brain Metastases from Non–small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
M6620 (VX-970)NCT03718091II223YesM6620 (VX-970) in Selected Solid Tumors
AZD6738NCT03682289II68NoPhase II Trial of AZD6738 Alone and in Combination with Olaparib
AZD6738NCT03462342II86NoCombination ATR and PARP Inhibitor (CAPRI) Trial with AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)
AZD6738NCT03787680II47NoTargeting Resistant Prostate Cancer with ATR and PARP Inhibition (TRAP Trial)
AZD6738NCT03328273I/II62NoA Study of AZD6738 and Acalabrutinib in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
AZD6738NCT03669601I50NoAZD6738 and Gemcitabine as Combination Therapy (ATRiUM)
AZD6738NCT03770429Ib52NoAZD6738 for Patients with Progressive MDS or CMML
AZD6738NCT02264678I250YesAscending Doses of AZD6738 in Combination with Chemotherapy and/or Novel Anticancer Agents
BAY1895344NCT03188965I219YesFirst-in-human Study of ATR Inhibitor BAY1895344 in Patients with Advanced Solid Tumors and Lymphomas
CHK1/2PrexasertibNCT02873975II50YesA Study of LY2606368 (Prexasertib) in Patients with Solid Tumors with Replicative Stress or Homologous Repair Deficiency
PrexasertibNCT03057145I24NoCombination Study of Prexasertib and Olaparib in Patients with Advanced Solid Tumors
PrexasertibNCT03495323I28NoA Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients with Advanced Solid Tumors
PrexasertibNCT02203513II153NoA Phase II Single-Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation-Associated Breast or Ovarian Cancer, Triple-Negative Breast Cancer, High-Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
PrexasertibNCT02808650I65NoPrexasertib in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors
PrexasertibNCT03735446I28NoPrexasertib in Combination with MEC in Relapsed/Refractory AML and High-Risk MDS – A Phase I Trial
SRA737NCT02797964I/II170Chk1 or ATR or other related geneA Phase 1/2 Trial of SRA737 in Subjects with Advanced Cancer
SRA737NCT02797977I/II140YesA Phase 1/2 Trial of SRA737 in Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone in Subjects with Advanced Cancer
Additional Trials Targeting ATM-Deficient Tumors
PARPOlaparibNCT02576444II64NoOLAParib COmbinations (OLAPCO)
OlaparibNCT03842228Ib102YesCopanlisib, Olaparib, and Durvalumab in Treating Patients with Metastatic or Unresectable Solid Tumors
OlapribNCT03009682II28YesOlaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients with HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations (SUKSES-B)
OlaparibNCT03012321II70YesAbiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA-Repair Defects
OlaparibNCT03786796II20YesStudy of Olaparib in Metastatic Renal Cell Carcinoma Patients with DNA-Repair Gene Mutations (ORCHID)
OlaparibNCT03570476Pilot15YesOlaparib Before Surgery in Treating Participants with Localized Prostate Cancer
OlaparibNCT03375307II60YesOlaparib in Treating Patients with Metastatic or Advanced Urothelial Cancer with DNA-Repair Defects
OlaparibNCT02734004I/II427NoA Phase I/II Study of MEDI4736 in Combination with Olaparib in Patients with Advanced Solid Tumors (MEDIOLA)
TalozaparibNCT03565991II200YesJavelin BRCA/ATM: Avelumab plus Talazoparib in Patients with BRCA or ATM-Mutant Solid Tumors
TalozaparibNCT02286687II150YesStudy of the PARP Inhibitor BMN 673 in Advanced Cancer Patients with Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)
TalozaparibNCT03330405Ib/2242NoJavelin Parp Medley: Avelumab plus Talazoparib In Locally Advanced or Metastatic Solid Tumors
TalozaparibNCT03377556II64YesLung-MAP: Talazoparib in Treating Patients with HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
TalozparibNCT02401347II58YesPhase II Talazoparib in BRCA1 + BRCA2 Wild-Type and Triple-Neg/HER2-Negative Breast Cancer/Solid Tumors
NiraparibNCT03209401I146YesNiraparib plus Carboplatin in Patients with Homologous Recombination Deficient Advanced Solid Tumor Malignancies
NiraparibNCT03207347II47YesA Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
RucaparibNCT02952534II360YesA Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)
  • NOTE: The table summarizes currently open clinical trials that directly or indirectly target ATM-deficient tumors. The trials were captured from a search on clinicaltrials.gov on March 2, 2019. Clinical trials that potentially accept pancreatic cancer patients are shown in bold.